References
- Druker BJ, Tamura S, Buchdunger E, et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
- Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML. Cancer Lett 2009;274:1–9.
- Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018–1029.
- Jabbour E, Kantarjian H, Jones D, et al Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767–1773.
- Shah NP, Nicoll JM, Nagar B, et al Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117–125.
- Branford S, Rudzki Z, Walsh S, et al High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472–3475.
- Kim SH, Kim D, Kim DW, et al Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol 2009. EPub: PMID: 19274615
- Ai Leen Ang ZPW, Li YY, Vallalan N, et al The M351T Bcr-Abl kinase mutation is uncommon in Asian patients with imatinib-resistant chronic myeloid leukemia: possible relationship with imatinib plasma levels. Blood 2008;112:2122a.
- Kuila N, Dash N, Sahoo DP, et al Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India. Leuk Lymphoma 2009;50:663–666.
- Rajappa S, Varadpande L, Paul T, et al Imatinib mesylate in early chronic phase chronic myeloid leukemia: experience from a developing country. Leuk Lymphoma 2008;49:554–558.
- Gupta A, Prasad K. Hematological and molecular response evaluation of CML patients on imatinib. J Assoc Physicians India 2007;55:109–113.
- Chu S, Xu H, Shah NP, et al Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093–2098.
- Lange T, Park B, Willis SG, Deininger MW. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 2005;4:1761–1766.
- Kang HY, Hwang JY, Kim SH, et al Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 2006;91:659–662.
- Nicolini FE, Corm S, Le QH, et al Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006;20:1061–1066.